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Objectives: Patient access (or risk-sharing) schemes are alternative market access agreements between healthcare
payers and medical product manufacturers for conditional coverage of promising health technologies. This study
aims to identify and characterize patient access schemes to date in the Asia-Pacific region.
Methods: We reviewed the literature on patient access schemes over the last two decades using publicly available
databases, Internet, and grey literature searches. We extracted key features of each scheme identified, including the
drug, clinical indication, stakeholders involved, and details of the scheme. We categorized schemes according to a
previously published taxonomy of scheme types and by country.
Results: We identified 3 schemes in South Korea, 5 in New Zealand, and 98 in Australia. Most (97.2%; n = 103)
schemes focused on pharmaceuticals, few on medical technologies. More than half of the schemes related to
treatments for cancer and inflammatory diseases such as rheumatoid arthritis. The majority (77.4%; n =82) involved
pricing arrangements. Evidence generation schemes were rarely used. About half (41.8%; n = 41) of schemes in
Australia were hybrid by nature, consisting of pricing arrangements with a conditional treatment continuation
component.
Conclusions: Australia has the most experience with patient access schemes and its experience may provide useful
insights for other Asia-Pacific countries. The main targets are pharmaceuticals likely to have high budget impact
(due to high per-patient costs and/or large volumes of use), and pharmaceuticals that may be adopted more widely
than indicated. With the proliferation of high-cost medicines, the use of schemes may increase to address rising
cost pressures, consumer demands, and uncertainties, while attempting to provide patient access to innovative care
within finite budgets. Future research is warranted to evaluate the performance of patient access schemes.
Keywords: Patient access schemes, Risk sharing, Managed entry, Conditional coverage, Health technology
assessment, High cost medicines, Access to medicinesIntroduction
Many countries and insurance schemes are pursuing
universal health coverage with the goal of ensuring
that all people have access to needed health services
without suffering financial hardship [1,2]. However,
healthcare systems grapple with the challenges of
funding clinically beneficial health services and med-
icines while ensuring that financing systems are
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unless otherwise stated.In an effort to improve the efficiency of rising health-
care expenditures, many systems evaluate whether ex-
pected additional health benefits of a new technology
justify its additional cost compared to existing treat-
ments (cost-effectiveness or ‘value-for-money’) [3-5].
Healthcare systems in the Asia-Pacific region that re-
quire proof of value-for-money in coverage of medical
technologies include Australia, New Zealand, Thailand,
South Korea, and Taiwan [6-10]. Even in systems that do
not explicitly consider cost, there is often a focus on
the magnitude of health benefits, which are informally
weighed against cost. Traditionally, coverage decisions
on medical technologies such as medicines and devicesis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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at launch and the price set by the manufacturer, payers
decide whether or not to reimburse a product. In recent
years, various types of conditional coverage decisions
have emerged. Patient access schemes (also known as
managed entry schemes or risk-sharing agreements) are
alternative market access agreements, typically between
payers and manufacturers, to enable provisional or con-
ditional coverage of promising health technologies
[4,5,11]. There are three broad categories of schemes [5].
First, outcome-based schemes (also known as performance-
based or effectiveness guarantee schemes) in which the
price, level, or nature of reimbursement are tied to clinical
or intermediate endpoints measured in the future and
ultimately related to patients’ quality or quantity of life.
Second, evidence generation schemes in which a positive
coverage decision is conditioned upon the collection of
additional evidence through clinical studies, which might
result in continued, expanded, or withdrawn coverage.
Third, financially-based schemes negotiate company contri-
butions to the cost of a product (e.g., discounts or rebates,
price-volume agreements, utilization caps) for a particular
patient or population without linking reimbursement to
health outcomes.
Interest in patient access schemes is growing due to
increasing cost pressures, the need to balance the inter-
ests of patients, clinicians, manufacturers, and other
stakeholders, and uncertainties due to incomplete in-
formation at the time that decisions must be made.
The necessary evidence to demonstrate incremental
effectiveness and cost-effectiveness of a new technol-
ogy is often not available at the time of launch [12].
Therefore, uncertainties exist about whether the tech-
nology will deliver the promised health gains in rou-
tine clinical practice. Clinical and cost-effectiveness
uncertainties result in budget uncertainties [12]. In
addition, costs of innovative products may bankrupt
households and threaten sustainability of systems. Pa-
tient access schemes offer an important option for
systems to allow (some) patients (early) access to
promising technologies that systems may not other-
wise fund. At the same time, these schemes may re-
duce the financial risks that payers face in making
decisions based on limited evidence, and in some
cases, they facilitate collection of more evidence to
support future decisions [4,5,11].
Little is known about experiences with patient ac-
cess schemes in Asia-Pacific countries. The purpose of
this study was to identify and categorize patient access
schemes in this region. The results of this study will
enhance understanding of the roles of patient access
schemes in emerging Asia-Pacific markets and inform
policy developments for enabling patient access to
promising technologies.Methods
We reviewed the literature on patient access schemes.
We searched in PubMed and Google Scholar for
English-language articles published through July 2012
using the following terms; ‘conditional coverage’, ‘condi-
tional reimbursement’, ‘managed entry’, ‘risk sharing’,
‘risk sharing agreement’, ‘risk sharing, pharmaceuticals’,
‘risk sharing scheme’, ‘coverage with evidence’, ‘value-
based pricing, pharmaceuticals’, ‘patient access scheme’,
‘pay back schemes’, ‘performance-based, pharmaceuti-
cals’, ‘outcome-based reimbursement, pharmaceuticals’,
‘reimbursement mechanisms, pharmaceuticals’, and ‘out-
come guarantee’. We scanned titles and abstracts to se-
lect relevant articles to review. The reference lists of
relevant articles were also reviewed for studies fitting
our criteria that our search strategy may have missed.
We also added relevant unpublished or ‘grey literature’
(reports, conference presentations, payer websites) that
were identified during our search.
We extracted key features of the schemes: the technol-
ogy, disease area, country, payer, manufacturer, scheme
type, and agreement details (when reported). We catego-
rized the schemes according to a published taxonomy [5]
of scheme types: (1) outcome-based schemes, (2) evidence
generation schemes, and (3) financially-based schemes.
These scheme types have generally been termed “risk shar-
ing schemes” or “patient access schemes” by payers or
pharmaceutical companies. Consistent with the literature
[13], we classified schemes with a “conditional treatment
continuation” component that limits continued subsidy of
medicines to patients who demonstrate a pre-specified
adequate clinical response as outcome-based schemes. We
deliberately included financially-based schemes, in con-
trast to previous reviews of patient access schemes that
focused on outcome-based schemes only [13]. Although
financially-based schemes do not directly address uncer-
tainties in clinical outcomes, they can address uncertain-
ties in cost-effectiveness and/or budget impact estimates.
Their use is increasing rapidly because they may be more
feasible than outcome-based schemes that require more
information and are administratively burdensome. We
did not limit our search to any country. We report on
schemes identified in Asia-Pacific markets.
Results
Search results
Using the search terms in PubMed and Google Scholar,
we found 2229 articles published between 1998 and July
2012. Reviewing article titles and abstracts, we excluded
commentaries and articles that did not describe specific
patient access schemes. Next, we reviewed the references
of remaining articles and grey literature sources for
additional examples of patient access schemes. Our search
identified 299 schemes described in 146 publicly available
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ports, 9 websites, and 13 conference presentations). From
these we selected the 106 examples from the Asia-Pacific
region.
Participating countries
We identified 106 patient access schemes in 3 countries
from the Asia-Pacific region (Table 1). Public payers
were involved in all schemes. Most (92.5%; n = 98)
have taken place in Australia (Table 2) [14-21]. The
Australian Pharmaceutical Benefits Advisory Committee
(PBAC) is an expert committee that reviews incremental
effectiveness and cost-effectiveness of medicines for cover-
age under the Pharmaceutical Benefits Scheme. The PBAC
has formally assessed evidence of cost-effectiveness since
1993 [4]. The Medical Benefits Advisory Committee is an
equivalent committee that evaluates medical devices for
coverage under the Medical Benefits Scheme.
Apart from Australia, we found 5 schemes in New
Zealand and 3 in South Korea. Table 3 summarizes the
schemes [22-25]. These countries also have established a
formal process for health technology assessment. Similar
to Australia, New Zealand has a national health insur-
ance for its people. The pharmaceutical management
agency was established in 1993 to make decisions about
drug coverage. The agency considers a number of factors,
including the clinical need, clinical benefits and risks,
cost-effectiveness, and budget impact of new drugs [26].
South Korea is the first country in Asia to officially adopt
economic evaluation for making drug reimbursementTable 1 Patient access schemes in the Asia-Pacific region







Outcome-based 21 - - 21
Evidence generation 3 - - 3
Financially-based 33 3 5 41
Hybrid* 41 - - 41
Conditions
Cancer 29 - 2 31
Inflammatory Conditions 28 - 1 29
Infectious Disease 7 - - 7
Pulmonary Hypertension 7 1 1 9
Other 27 2 1 30
Technology
Pharmaceuticals 95 3 5 103
Medical devices 3 - - 3
Subtotal 98 3 5 106
*Hybrid schemes involved both pricing arrangements and conditional
treatment continuationdecisions since January 2008. The Health Insurance Review
Agency is responsible for reviewing the cost-effectiveness
and budget impacts of new drugs for reimbursement under
South Korea’s National Health Insurance [27].
Types of medical products
Almost all patient access schemes focused on pharma-
ceuticals (97.2%; n = 103), few on medical technologies.
More than half of schemes covered treatments for non-
communicable diseases, predominantly cancer (n = 31)
and inflammatory diseases (n = 29) such as rheumatoid
arthritis. Schemes in Australia were largely established
for technologies with high budget impact due to high
cost per patient (e.g., adalimumab, which costs approxi-
mately $20,000 per patient-year) or large volumes of use
(e.g., dabigatran for prevention of stroke or systemic em-
bolism), as well as for products that may be used beyond
their approved indications (e.g., entecavir that is subsi-
dized only for chronic hepatitis B in adults with evidence
of active liver inflammation). Similarly, New Zealand tar-
geted new products with high cost per-patient or large
volumes of use. Instead of individual drugs, the schemes
in South Korea targeted the entire class of older medica-
tions with high budget impact due to large volumes of
use (e.g., hyperlipidemia medications).
Outcome-based schemes
Nearly two-thirds of schemes in Australia (63.3% n = 62;
Table 2) included a “conditional treatment continuation”
component that limits continued subsidy of high-cost
medicines to patients who demonstrate an adequate
clinical response. These schemes specify strict criteria
for both initial and continued access. For example, the
scheme for adalimumab for rheumatoid arthritis requires
confirmation of clinical improvement at 3 months (mea-
sured by reductions in the total number of affected joints
and in levels of inflammation markers) for continued sub-
sidy [28]. In the scheme for bosenten in Australia, price
was directly linked to the observed survival of patients
treated with bosentan to confirm the clinical benefits
(i.e., survival) and cost-effectiveness assumed at the
time of assessment [29].
Evidence generation schemes
We found three schemes with an evidence generation
component in Australia, all focused on medical tech-
nologies: positron emission tomography, deep brain
stimulators, and endovascular aneurysm repair (Table 2).
In all three cases, the Australian government agreed to
provide interim funding for access to the technology and
to support collection of relevant clinical (and cost) infor-
mation [15]. The manufacturers did not share the finan-
cial costs to generate evidence.
Table 2 Identified patient access schemes in Australia
Technology Indication Company Payer Type Source
Cancer (n = 29)
Dasatinib CML Bristol-Myers Squibb Australia
Pty Ltd
PBS Outcome-based Medicare Australia [14]
Nilotinib CML Novartis Pharmaceuticals Australia
Pty Ltd
PBS Outcome-based Medicare Australia [14]
Imatinib GIST, adjuvant Novartis Pharmaceuticals Australia
Pty Ltd
PBS Outcome-based Medicare Australia [14]
Imatinib GIST, metastatic Novartis Pharmaceuticals Australia
Pty Ltd
PBS Outcome-based Medicare Australia [14]
Lapatinib Late stage metastatic breast cancer GlaxoSmithKline Australia Pty Ltd PBS Outcome-based Medicare Australia [14]




PBS Outcome-based Medicare Australia [14]
Pazopanib RCC GlaxoSmithKline Australia Pty Ltd PBS Financially-based;
Outcome-based
Public Summary Document [18]
Bevacizumab Metastatic colorectal cancerr Roche Products Pty Ltd PBS Financially-based;
Outcome-based
Public Summary Document [18]
Sorafenib Advanced hepatocellular carcinoma Bayer Australia Ltd PBS Financially-based;
Outcome-based
Public Summary Document [18]
PET Staging of newly diagnosed NSCLC, esophageal cancer,
cancer of gastro-esophageal junction, head and neck
cancer, suspected residual/metastatic/recurrent colorectal
cancer, melanoma, head and neck cancer, ovarian cancer
Not specified MBS Evidence generation Stafinski et al. 2010 [15]
Exemestane Oestrogen-receptor positive advanced breast cancer in
post-menopausal women
Pfizer Australia Pty Ltd PBS Financially-based Public Summary Document [18]
Imiquimod Superficial basal cell carcinoma 3 M Pharmaceuticals Pty Ltd PBS Financially-based Public Summary Document [18]
Letrozole Advanced breast cancer in postmenopausal women Novartis Pharmaceuticals Australia
Pty Ltd
PBS Financially-based Public Summary Document [18]
Docetaxel SCCHN Sanofi-Aventis Australia Pty Ltd PBS Financially-based Public Summary Document [18]
Sunitinib RCC Pfizer Australia Pty Ltd PBS Financially-based PBS Schedule [16], Public Summary
Document [18]
Cetuximab K-RAS wild mCRC Merck Serono Australia Pty Ltd PBS Financially-based Public Summary Document [18]
Vemurafenib Untreated unresectable stage IIIC or stage IV melanoma Roche Products Pty Ltd PBS Financially-based Public Summary Document [18]




PBPA Relativity Sheets [17], Public
Summary Document [18], Medicare
Australia [14]




PBPA Relativity Sheets [17], Public
Summary Document [18], Medicare
Australia [14]













Table 2 Identified patient access schemes in Australia (Continued)
Financially-based;
Outcome-based
Azacitidine AML Celgene Pty Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Medicare Australia [14]
Azacitidine Myelodysplastic syndrome Celgene Pty Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Medicare Australia [14]




PBPA Relativity Sheets [17], Medicare
Australia [14]
Trastuzumab HER2+ early breast cancer Roche Products Pty Ltd PBS Financially-based;
Outcome-based
PBPA Relativity Sheets [17], Medicare
Australia [14]
Sunitinib GIST Pfizer Australia Pty Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Medicare Australia [14]
Lenalidomide Myelodysplastic syndrome Celgene Pty Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Medicare Australia [14]
Lenalidomide Multiple myeloma Celgene Pty Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Medicare Australia [14]
Bortezomib Multiple myeloma Janssen-Cilag Pty Ltd PBS Financially-based,
Outcome-based
PBS Schedule [16], PBPA Relativity Sheets
[17], Public Summary Document [18],
Medicare Australia [14]
Erlotinib Non-small cell lung cancer Roche Products Pty Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Medicare Australia [14]
Inflammatory Conditions (n = 28)
Adalimumab Ankylosing spondylitis AbbVie Pty Ltd PBS Outcome-based Medicare Australia [14]
Etanercept Ankylosing spondylitis Pfizer Australia Pty Ltd PBS Outcome-based Medicare Australia [14]
Golimumab Ankylosing spondylitis Janssen-Cilag Pty Ltd PBS Outcome-based Medicare Australia [14]
Infliximab Ankylosing spondylitis Janssen-Cilag Pty Ltd PBS Outcome-based Medicare Australia [14]
Adalimumab Crohn’s disease AbbVie Pty Ltd PBS Outcome-based Medicare Australia [14]
Infliximab Complex refractory fistulising Crohn’s disease Janssen-Cilag Pty Ltd PBS Outcome-based Medicare Australia [14]
Adalimumab Juvenile arthritis AbbVie Pty Ltd PBS Outcome-based Medicare Australia [14]
Etanercept Juvenile arthritis Pfizer Australia Pty Ltd PBS Outcome-based Medicare Australia [14]
Adalimumab Psoriatic arthritis AbbVie Pty Ltd PBS Outcome-based Medicare Australia [14]
Golimumab Psoriatic arthritis Janssen-Cilag Pty Ltd( PBS Outcome-based Medicare Australia [14]
Infliximab Psoriatic arthritis Janssen-Cilag Pty Ltd PBS Outcome-based Medicare Australia [14]
Pimecrolimus Atopic dermatitis who are over 18 years of age Novartis Pharmaceuticals Australia PBS Financially-based Public Summary Document [18]
Infliximab Crohn’s disease Janssen-Cilag Pty Ltd PBS Financially-based;
Outcome-based
PBPA Relativity Sheets [17], Medicare
Australia [14]
Adalimumab Complex refractory fistulising Crohn’s disease AbbVie Pty Ltd PBS Financially-based;
Outcome-based














Table 2 Identified patient access schemes in Australia (Continued)
Tocilizumab Juvenile arthritis Roche Products Pty Ltd PBS Financially-based;
Outcome-based
PBPA Relativity Sheets [17], Medicare
Australia [14]




PBS Schedule [16], Medicare Australia [14]
Infliximab RA Janssen-Cilag Pty Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Lu et al. 2007 [33],
Pugatch et al. 2010 [21], Medicare
Australia [14]
Rituximab RA Roche Products Pty Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Lu et al. 2007 [33],
Pugatch et al. 2010 [21], Medicare
Australia [14]
Tocilizumab RA Roche Products Pty Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Medicare Australia [14]
Certolizumab Pegol RA UCB Australia Proprietary Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Medicare Australia [14]
Adalimumab RA AbbVie Pty Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Lu et al. 2007 [33],
Pugatch et al. 2010 [21], Medicare
Australia [14]
Golimumab RA Janssen-Cilag Pty Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Medicare Australia [14]
Etanercept RA Pfizer Australia Pty Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Lu et al. 2007 [33],
Pugatch et al. 2010 [21], Medicare
Australia [14]
Adalimumab Severe chronic plaque psoriasis AbbVie Pty Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Lu et al. 2007 [33],
Pugatch et al. 2010 [21], Medicare
Australia [14]
Etanercept Severe chronic plaque psoriasis Pfizer Australia Pty Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Medicare Australia [14]
Infliximab Severe chronic plaque psoriasis Janssen-Cilag Pty Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Medicare Australia [14]
Ustekinumab Severe chronic plaque psoriasis Janssen-Cilag Pty Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Medicare Australia [14]
Etanercept Severe chronic plaque psoriasis under 18 Pfizer Australia Pty Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Medicare Australia [14]
Infectious Diseases (n = 7)
Abacavir HIV infection ViiV Healthcare Pty Ltd PBS Financially-based Robertson et al. 2009 [19], Adamski et al.
2010 [20]
Tipranavir HIV infection Boehringer Ingelheim Pty Ltd PBS Financially-based PBS Schedule [16], Public Summary
Document [18]
Entecavir Chronic hepatitis B in adults 16 years and older with
evidence of active liver inflammation
Bristol-Myers Squibb Australia
Pty Ltd













Table 2 Identified patient access schemes in Australia (Continued)
Boceprevir Chronic genotype 1 hepatitis C infection Merck Sharp & Dohme (Australia)
Pty Ltd
PBS Financially-based Public Summary Document [18]
Telaprevir Chronic genotype 1 hepatitis C Janssen-Cilag Pty Ltd PBS Financially-based Public Summary Document [18]
Posaconazole Invasive fungal infections, not responsive to or intolerant
of, alternative therapy
Schering-Plough Pty Ltd PBS Financially-based Public Summary Document [18]
Posaconazole Prophylaxis of invasive fungal infections among high risk
patients
Schering-Plough Pty Ltd PBS Financially-based Public Summary Document [18]
Pulmonary Hypertension (n = 7)
Sildenafil PPH or PAH Pfizer Australia Pty Ltd PBS Outcome-based PBS Schedule [16], Medicare Australia [14]
Tadalafil PPH or PAH Eli Lilly Australia Pty Ltd PBS Outcome-based PBS Schedule [16], Medicare Australia [14]
Treprostinil Sodium PPH or PAH Orphan Australia Pty Ltd PBS Financially-based Public Summary Document [18]
Ambrisentan PPH or PAH GlaxoSmithKline Australia Pty Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Medicare Australia [14]




PBS Schedule [16], PBPA Relativity Sheets
[17], Public Summary Document [18],
Medicare Australia [14]
Epoprostenol PPH or PAH GlaxoSmithKline Australia Pty Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], PBPA Relativity Sheets
[17], Public Summary Document [18],
Medicare Australia [14]
Iloprost trometamol PPH or PAH Bayer Australia Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Medicare Australia [14]
Other (n = 27)
Modafinil Narcolepsy bioCSL (Australia) Pty Ltd PBS Outcome-based Medicare Australia [14]
Verteporfin Age-related macular degeneration Novartis Pharmaceuticals Australia
Pty Ltd
PBS Outcome-based Medicare Australia [14]
Deep brain stimulation Patients with Parkinson's disease no longer responsive to
drug therapy
Not specified MBS Evidence generation Stafinski et al. 2010 [15]
EVAR Abdominal aortic aneurysm Not specified MBS Evidence generation Stafinski et al. 2010 [15]
Dabigatran Prevention of stroke or systemic embolism in patients with
non-valvular atrial fibrillation
Boehringer Ingelheim Pty Ltd PBS Financially-based Public Summary Document [18]
Atomoxetine
Hydrochloride
ADHD diagnosed between the ages of 6 and 18 years Eli Lilly Australia Pty Ltd PBS Financially-based Public Summary Document [18]




Public Summary Document [18]
Cinacalcet Hydrochloride End stage renal disease receiving dialysis who have
uncontrolled secondary hyperparathyroidism






Severe spasticity of the upper limb in adults following a
stroke, as an adjunct to physical therapy













Table 2 Identified patient access schemes in Australia (Continued)
Fentanyl citrate Fentanyl lozenges for the treatment of breakthrough pain Orphan Australia Pty Ltd PBS Financially-based Public Summary Document [18]
Natalizumab RRMS Biogen Idec Australia Pty Ltd PBS Financially-based Public Summary Document [18]
Paliperidone Schizophrenia Janssen-Cilag Pty Ltd PBS Financially-based Public Summary Document [18]
Botulinum toxin type a
purified neurotoxin
complex
Moderate to severe spasticity of the upper limb in adults
following a stroke as an adjunct to physical therapy
Allergan Australia Pty Ltd PBS Financially-based Public Summary Document [18]
Tenofovir Disoproxil
Fumarate
Treatment of chronic hepatitis B Gilead Sciences Pty Ltd PBS Financially-based Public Summary Document [18]
Pramipexole
hydrochloride
Idiopathic Parkinson disease Boehringer Ingelheim Pty Ltd PBS Financially-based Public Summary Document [18]




PBS Financially-based Public Summary Document [18]
Ticagrelor ACS, MI, or unstable angina AstraZeneca Pty Ltd PBS Financially-based Public Summary Document [18]
Pregabalin Neuropathic pain Pfizer Australia Pty Ltd PBS Financially-based Public Summary Document [18]
Rivaroxaban Acute symptomatic DVT Bayer Australia Ltd PBS Financially-based Public Summary Document [18]
Aztreonam Pseudomonas aeruginosa infection in patients with cystic
fibrosis
Gilead Sciences Pty Ltd PBS Financially-based Public Summary Document [18]
Crinone (progesterone
gel)
Supplement progesterone in women who have luteal
phase defect
Merck Serono PBS Financially-based Robertson et al. 2009 [19], Adamski et al.
2010 [20]
Deferasirox (Exjade) Chronic iron overload in patients with disorders of
erythropoiesis
Novartis PBS Financially-based Robertson et al. 2009 [19], Adamski et al.
2010 [20]




PBS Schedule [16], Medicare Australia [14]
Aflibercept Age-related macular degeneration Bayer Australia Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Medicare Australia [14]




PBS Schedule [16], PBPA Relativity Sheets
[17], Public Summary Document [18],
Medicare Australia [14]
Eltrombopag Severe chronic immune idiopathic thrombocytopenic
purpura
GlaxoSmithKline Australia Pty Ltd PBS Financially-based;
Outcome-based
PBPA Relativity Sheets [17], Medicare
Australia [14]
Romiplostim Severe chronic immune idiopathic thrombocytopenic
purpura
Amgen Australia Pty Ltd PBS Financially-based;
Outcome-based
PBS Schedule [16], Medicare Australia [14]
ACS = Acute Coronary Syndromes; ALL = Acute Lymphoblastic Leukemia; AML = Acute Myeloid Leukemia; CML = Chronic Myeloid Leukemia; DVT = Deep Vein Thrombosis; EVAR = endovascular aneurysm repair;
GIST = Gastrointestinal Stromal Tumor; MBS =Medicare Benefits Schedule; mCRC =Metastatic Colorectal Cancer; MI = Myocardial Infarction; PAH = Pulmonary Arterial Hypertension; PBS = Pharmaceutical Benefits













Table 3 Identified patient access schemes in the Asian-Pacific region (excluding Australian examples)
























285 of the 1226 hypertension drugs instituted price reductions following
reassessment of clinical usefulness & price. Drugs were delisted if they failed to
show a level of clinical usefulness or if their prices were higher than 80 percentile of
the highest price among drugs containing the same ingredients. If the company
accepted price cuts, the price was to be lowered to the level of the 80 percentile
within 3 years





















Extended coverage for a specified number of patients Raftery 2008 [23]
Trastuzumab Breast cancer Roche PHARMAC Financially-
based






Offered overall price reduction Raftery 2008 [23]
Atorvastatin Hypertension Pfizer PHARMAC Financially-
based
Price volume agreements; manufacturer committed to pay for the drug if the sales








Adalimumab spending is probably overstated due to a risk sharing agreement
between the sponsor and PHARMAC, which involves rebates paid by the sponsor
once Government spending reaches a certain level
Access Economics
report for Arthritis New
Zealand 2010 [25]
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Financially-based schemes involving price reductions,
price-volume agreements, or utilization caps were the
most common risk-sharing schemes across the Asia-Pacific
region (77.4%; n = 82). We identified 3 in South Korea, 5 in
New Zealand, and 74 schemes in Australia. Forty-one of 74
schemes in Australia were hybrid schemes that involved
both pricing arrangements and conditional treatment
continuation.
Discussion
In attempts to provide access to promising technologies,
many countries are assessing the potential applicability
of patient access schemes for their markets; these
schemes typically involve novel arrangements between
payers and manufacturers. We reviewed the literature on
patient access schemes in the last two decades, with a
focus on experiences in the Asia-Pacific region. We
found a few schemes from South Korean and New
Zealand, and many more schemes in Australia. Though
different in their development and implementation,
these schemes have arisen in response to cost pressures,
demands from key stakeholders, and the inherent uncer-
tainties in the health value and estimated budget impact
of medical products in real-world settings. Pharmaceuticals
account for nearly all identified schemes. The preponder-
ance of pharmaceutical schemes may reflect the different
evidence profiles at product launch, the higher budget im-
pact of pharmaceuticals versus devices, and/or the different
intellectual property and patent environments. There do
not appear to be guidelines on when patient access schemes
are applied or which type of scheme is most appropriate in
a given circumstance. However, our findings suggest that
the main targets are pharmaceuticals likely to have high
budget impact due to high per-patient acquisition costs
and/or potential large volumes of use, and pharmaceuticals
likely to be used beyond their approved indications.
In the Asia-Pacific region, Australia has the most ex-
perience with patient access schemes. This may reflect
the negotiating power and extensive experience in tech-
nology assessment, due to the design of the regulatory,
institutional, and policy structures for medicines benefit
decisions in the Australian publicly-funded national
healthcare system [4,6]. High-cost medicines for treat-
ment of cancer and inflammatory diseases were the tar-
gets of more than half of the schemes in Australia.
Typical outcome-based schemes, in which the price or
level of reimbursement is tied to achieving intermediate
or final clinical endpoints, have rarely been used in
Australia, with bosentan being the only example. Imple-
menting outcome-based schemes is complex: they require
detailed longitudinal information on patient clinical status
(e.g., disease severity and progression, comorbidities) [30];
they require substantial financial, human, and infrastructureresources for monitoring of patients and financial
transactions related to treatments [31]; and they re-
quire a mechanism for adjusting price or level of reim-
bursement when explicit clinical endpoints are not
reached. Instead, Australia limits continued subsidy of
high-cost medicines to patients who demonstrate an
adequate response, known as “conditional treatment
continuation” policies, which are often coupled with
pricing arrangements, that is, hybrid schemes. Initial
access is also restricted to a small pool of patients largely
based on disease severity and non-responsiveness to less
expensive therapeutic alternatives. Criteria restricting both
initial and continued access aim to maximize value-for-
money and control costs. While some evidence suggests
that such policies can cap spending [28,32], whether they
achieve value-for-money or if patients who need the
medicines actually gained access should be investigated.
Further, strict initial and continued access criteria are eth-
ically challenging as individual patients may just missed
the arbitrary threshold for access [33,34].
Evidence generation schemes were also rarely used in
the Asia-Pacific region, possibly due to the complexity
in tracking patient outcomes and the additional costs
and administrative burden involved to operate these
schemes.
In contrast, we found that financially-based schemes
were common, possibly due to fewer operational chal-
lenges. Price-volume agreements and utilization caps
have been in place for more than a decade in Australia
[19]. Typically, product prices are reduced if sales ex-
ceed pre-agreed volumes, or expenditures refunded by
the manufacturer if government expenditures exceed a
pre-agreed cap or threshold. Price-volume agreements
can shift cost considerations from the payer to the
manufacturer, which is important especially if there
are concerns that (i) new medicines will be prescribed
to a wider population than envisaged, (ii) the patients
prescribed the drug will not always be those most
likely to gain the greatest benefit [4,11,35], and/or (iii)
the product does not result in the expected clinical
benefits. Expectations are that manufacturers will tar-
get promotion in accordance with approved prescrib-
ing requirements. Details of patient access schemes (e.
g., capped prices, negotiated volumes) are generally
unavailable to the public [19].
Our study has several limitations. The review focused
on the Asia-Pacific region; however, the investigators
were limited to the English language literature; schemes
that were described only in other languages have not
been included. Given the sensitive nature of contracts in
this field, it is likely information on schemes remains un-
published. Manufacturers will be reluctant to disclose
details about patient access schemes if such information
will be available to other countries that use external
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mated the total number of patient access schemes in
Asia-Pacific countries. Nevertheless, this study provides
insights about what types of products are commonly tar-
gets for patient access schemes and about recent experi-
ences in the Asia-Pacific region that may inform the
development of future schemes.
Although beyond the scope of this review, we noted
that industry-sponsored patient assistance programs
were implemented in several countries to improve access
to medicines. For instance, the Glivec International Pa-
tient Assistance Program, implemented since 2001 in 81
low and middle-income countries (including China,
India, Indonesia, Thailand, and Vietnam), has provided
access to imatinib for patients with specific types of
leukemia or gastrointestinal cancer [36]. The MUSANDA
patient assistance program, implemented in the United
Arab Emirates, supports access to ranibizumab for age-
related macular degeneration. Although payers are usually
not involved in industry-sponsored patient assistance pro-
grams, these programs can provide interim access to in-
novative medicines while payer-industry patient access
schemes are under negotiation; they can complement
payer-industry patient access schemes by providing treat-
ments for individual patients who are unable to self-fund
treatments and who have no third-party payer; or they can
become a vehicle for implementing a payer-industry pa-
tient access scheme, as has happened for coverage of
imatinib in Thailand [37].
Globally, forecasts estimate that spending on new
biologic agents will outpace overall spending growth on
medicines and represent about 20% of the estimated US
$1.2 trillion total pharmaceutical market by 2017 [38].
The recent availability of sofosbuvir, a new, curative
treatment for hepatitis C, a disease that is highly preva-
lent in many low and middle-income countries, high-
lights the need for innovation in medicines financing.
Refined patient access schemes may constitute much-
needed innovations in financing arrangements that pro-
vide equitable and affordable access for those who need
the new medicines. Payers have an incentive to develop
strategies that can help control costs while ensuring
patient access to medical products that benefit health.
Patient access schemes may also mitigate the negative
impacts of uncertainties in cost-effectiveness and budget
impact estimates, and shift payer and manufacturer
focus to improving patient outcomes in real-world set-
tings – the ultimate goal of medical care. Payers have
different ranges of authority over pricing, access, and
evidence generation; some are more limited in the types
of coverage decisions or access schemes they can con-
sider, which may explain some of the variation in use of
schemes between countries. Manufacturers are likely to
prefer patient access schemes over a denial of coverageor explicitly reduced pricing, in part because patient ac-
cess schemes can keep the real reimbursement prices
confidential allowing them to tier prices by markets
without the threat of external reference pricing [5,13].
There is little evidence on whether patient access
schemes achieve their intended goals; they are a
relatively recent development and the details of such
agreements are usually confidential. However, key
stakeholders appear willing to at least discuss types of
schemes that can enable patient access to needed
medicines [4,31,33]. Future studies should generate
evidence on whether patients who need the medicines
actually receive and benefit from them; whether
schemes make high quality care more affordable for
households and systems; whether they provide incen-
tives for manufacturers to continue to invest in
products that meet unmet needs; and whether data
collected as part of the schemes confirm estimated
cost-effectiveness or long-term benefits. Such evidence
about potential benefits and costs is needed to inform
the adoption of patient access schemes globally. Other
factors that may affect their adoption center around
operational challenges such as administrative burden and
difficulty in tracking patient outcomes in healthcare deliv-
ery and financing systems [4,5,13,28,30-34,39], as well as
the transparency and perceived fairness of the complex
decisions on the establishment of patient access schemes
and criteria for access [33,34]. Research is needed to com-
pare costs of administration and operation on the payer
side and effects on pricing strategies globally on the
pharmaceutical company side between patient access
schemes and upfront discounts in drug prices.
Conclusions
Patient access schemes offer an important option for
healthcare systems to allow patient access to promis-
ing technologies that may not otherwise be funded.
Our study adds to existing knowledge by identifying
and characterizing published patient access schemes
in the Asia-Pacific region. Financially-based access
schemes are most common. Australia tends to couple
conditional treatment continuation with financial ar-
rangements to provide further assurance. The main
targets of patient access schemes are pharmaceuticals
likely to have high budget impact due to high per-
patient costs and/or large volumes of use, and phar-
maceuticals that may be adopted more widely than
indicated. With the rapid proliferation of high-cost
medicines, these schemes may increasingly be used to
enable access to innovative care within finite budgets.
Future research is needed to generate evidence about
the effectiveness and economic, administrative, and
company pricing policy consequences of patient access
schemes.
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